Summary

Eligibility
for people ages up to 29 years (full criteria)
Location
at UCLA UCSF
Dates
study started
completion around

Description

Summary

This pilot phase II trial studies how well rituximab and latent membrane protein (LMP)-specific T-cells work in treating pediatric solid organ recipients with Epstein-Barr virus-positive, cluster of differentiation (CD)20-positive post-transplant lymphoproliferative disorder. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. LMP-specific T-cells are special immune system cells trained to recognize proteins found on post-transplant lymphoproliferative disorder tumor cells if they are infected with Epstein-Barr virus. Giving rituximab and LMP-specific T-cells may work better in treating pediatric organ recipients with post-transplant lymphoproliferative disorder than rituximab alone.

Official Title

A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-Specific Cytotoxic T-Lymphocytes (LMP-TC) in Pediatric Solid Organ Recipients (SOT) With EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD)

Details

Keywords

EBV-Related Post-Transplant Lymphoproliferative Disorder, Monomorphic Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder, Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder, Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder, Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder, Lymphoproliferative Disorders, Recurrence, Rituximab, Immunological Antineoplastic Agents, Antibodies, Immunoglobulins, Monoclonal Antibodies, Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes, LMP-TC

Eligibility

Locations

  • Mattel Children's Hospital UCLA
    Los Angeles California 90095 United States
  • UCSF Medical Center-Mission Bay
    San Francisco California 94158 United States
  • Children's Hospital Los Angeles
    Los Angeles California 90027 United States
  • Lucile Packard Children's Hospital Stanford University
    Palo Alto California 94304 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Children's Oncology Group
ID
NCT02900976
Phase
Phase 2 research study
Study Type
Interventional
Participants
About 18 people participating
Last Updated